Where to buy tremelimumab

Tremelimumab (tremelimumab) is a humanized immune checkpoint inhibitor drug. It belongs to the anti-CTLA-4 antibody category and is mainly used to treat hepatocellular carcinoma (uHCC) and non-small cell lung cancer (NSCLC). CTLA-4 (antigen cytotoxic T lymphocyte-associated antigen-4) is a protein located on the surface of T cells that inhibits T cell immune responses.

Temimumab binds and inhibitsCTLA-4, preventing it from binding to inhibitory molecules, thereby releasing the inhibition of T cell activity and enhancing the immune system's ability to attack tumor cells. TistumumabThis cytotoxic agent can reduce tumor growth. It binds to its target human CTLA-4 with high selectivity for 2 and subnanomolar affinity. In in vitro blood stimulation experiments using peripheral blood mononuclear cells (PBMCs) from healthy volunteers and cancer patients, temsitumumab led to an increase in IL-2 production in a dose-dependent manner, indicating that temsitumumab stimulated T cell-mediated cytotoxicity and also increased the proliferation of effector T cells. In vitro, there is no evidence that temsitumumab or drug binding to Fc receptors induces nonspecific cytokine release.

Tesetumumab is an emerging cancer immunotherapy drug. It is a prescription drug and has not yet been launched in China. Therefore, it has not been included in the medical insurance list. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab the original drug has been on the market overseas for a short time and is sold under the trade name Imjudo. The price is not yet clear, and there are currently no generic versions of temsitumumab produced and launched. For specific prices and drug details, please consult a medical consultant.